FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3131210460> ?p ?o ?g. }

• W3131210460 endingPage "21" @default.
• W3131210460 startingPage "PS14" @default.
• W3131210460 abstract "Abstract Background: Inflammatory breast cancer (IBC) is the most aggressive locally advanced breast cancer subtype. It is associated with loco-regional recurrence rates of 12-25%, and neoadjuvant chemotherapy (NAC) followed by modified radical mastectomy and comprehensive chest wall and regional nodal radiotherapy remain the standard of care. As has been demonstrated in non-IBC, achievement of pathologic complete response (pCR) has been shown to be associated with improved loco-regional control, recurrence-free and overall survival. Advances in NAC for IBC have resulted in improved pCR rates in both the breast and the axilla, with overall axillary pCR rates of approximately 30%, reaching as high as 67% in patients with HER2-positive disease receiving HER2-directed therapy. Hypothesis: Sentinel lymph node biopsy (SLNB) may be feasible in IBC patients who experience a good clinical and pathologic response in the axilla to NAC. Primary Objective: To evaluate the sentinel lymph node (SLN) identification rate in stage III IBC patients who experience cN0 status at completion of NAC. Secondary Objective: To assess the incidence of lymphedema following standard local-regional therapy for IBC. Methods and Study procedures: In this feasibility study, 50 patients with cT4dN0-2M0 IBC will be enrolled in order to evaluate 40 patients whose axillary nodal status becomes cN0 upon completion of NAC. All patients will undergo a research breast biopsy and lymphoscintigram pre and post NAC to evaluate lymphatic drainage patterns and patency of breast and axillary lymphatics. Post NAC lymphoscintigraphy will be appropriately timed for pre-operative SLN mapping and all patients will undergo SLNB using dual tracers (Tc99 Sulfur colloid and blue dye) with immediate axillary lymph node dissection (ALND), at the time of mastectomy. The patient-reported Lymphedema Symptom Intensity and Distress Survey (LSIDS-A) will be collected at 6 timepoints. Patients will be followed for 2 years post-surgery for oncologic outcomes. Correlatives: We plan to evaluate genetic and phenotypic heterogeneity in IBC and to assess markers of angiogenesis and lymph-angiogenesis associated with IBC, as well as to explore immunologic aspects of the tumor microenvironment and their association with pCR. Statistics: The identification rate will be calculated as number of patients in whom SLNs were successfully identified over the number of patients with cN0 disease after NAC in whom SLN mapping was attempted. Using a Simon two-stage design (α=.10, β=.10), a SLN identification rate of ≥90% would result in considering this procedure feasible whereas an identification rate of ≤75% (null hypothesis) would lead to the conclusion that it is not feasible. In the first stage, if greater than 18 of 25 patients have SLNs identified, then a total of 40 patients will be enrolled. If fewer than 33 of 40 patients have SLN identified, then the null hypothesis is rejected. Citation Format: Faina Nakhlis, Meredith Regan, Heather Jacene, Beth Harrison, Jennifer Bellon, Jean Landry, Eren Yeh, Elizabeth Mittendorf, Beth Overmoyer, Tari King. Refining loco-regional therapy for inflammatory breast cancer protocol in progress [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS14-21." @default.
• W3131210460 created "2021-03-01" @default.
• W3131210460 creator A5001573761 @default.
• W3131210460 creator A5012484312 @default.
• W3131210460 creator A5017334876 @default.
• W3131210460 creator A5019396960 @default.
• W3131210460 creator A5024690691 @default.
• W3131210460 creator A5028426531 @default.
• W3131210460 creator A5029062544 @default.
• W3131210460 creator A5058888805 @default.
• W3131210460 creator A5076310424 @default.
• W3131210460 creator A5081145734 @default.
• W3131210460 date "2021-02-15" @default.
• W3131210460 modified "2023-10-03" @default.
• W3131210460 title "Abstract PS14-21: Refining loco-regional therapy for inflammatory breast cancer protocol in progress" @default.
• W3131210460 doi "https://doi.org/10.1158/1538-7445.sabcs20-ps14-21" @default.
• W3131210460 hasPublicationYear "2021" @default.
• W3131210460 type Work @default.
• W3131210460 sameAs 3131210460 @default.
• W3131210460 citedByCount "0" @default.
• W3131210460 crossrefType "journal-article" @default.
• W3131210460 hasAuthorship W3131210460A5001573761 @default.
• W3131210460 hasAuthorship W3131210460A5012484312 @default.
• W3131210460 hasAuthorship W3131210460A5017334876 @default.
• W3131210460 hasAuthorship W3131210460A5019396960 @default.
• W3131210460 hasAuthorship W3131210460A5024690691 @default.
• W3131210460 hasAuthorship W3131210460A5028426531 @default.
• W3131210460 hasAuthorship W3131210460A5029062544 @default.
• W3131210460 hasAuthorship W3131210460A5058888805 @default.
• W3131210460 hasAuthorship W3131210460A5076310424 @default.
• W3131210460 hasAuthorship W3131210460A5081145734 @default.
• W3131210460 hasConcept C121608353 @default.
• W3131210460 hasConcept C126322002 @default.
• W3131210460 hasConcept C126838900 @default.
• W3131210460 hasConcept C141071460 @default.
• W3131210460 hasConcept C143998085 @default.
• W3131210460 hasConcept C146357865 @default.
• W3131210460 hasConcept C151730666 @default.
• W3131210460 hasConcept C2775934546 @default.
• W3131210460 hasConcept C2776608951 @default.
• W3131210460 hasConcept C2777757722 @default.
• W3131210460 hasConcept C2780212769 @default.
• W3131210460 hasConcept C2780839634 @default.
• W3131210460 hasConcept C2781392513 @default.
• W3131210460 hasConcept C2910733956 @default.
• W3131210460 hasConcept C509974204 @default.
• W3131210460 hasConcept C530470458 @default.
• W3131210460 hasConcept C71924100 @default.
• W3131210460 hasConcept C86803240 @default.
• W3131210460 hasConceptScore W3131210460C121608353 @default.
• W3131210460 hasConceptScore W3131210460C126322002 @default.
• W3131210460 hasConceptScore W3131210460C126838900 @default.
• W3131210460 hasConceptScore W3131210460C141071460 @default.
• W3131210460 hasConceptScore W3131210460C143998085 @default.
• W3131210460 hasConceptScore W3131210460C146357865 @default.
• W3131210460 hasConceptScore W3131210460C151730666 @default.
• W3131210460 hasConceptScore W3131210460C2775934546 @default.
• W3131210460 hasConceptScore W3131210460C2776608951 @default.
• W3131210460 hasConceptScore W3131210460C2777757722 @default.
• W3131210460 hasConceptScore W3131210460C2780212769 @default.
• W3131210460 hasConceptScore W3131210460C2780839634 @default.
• W3131210460 hasConceptScore W3131210460C2781392513 @default.
• W3131210460 hasConceptScore W3131210460C2910733956 @default.
• W3131210460 hasConceptScore W3131210460C509974204 @default.
• W3131210460 hasConceptScore W3131210460C530470458 @default.
• W3131210460 hasConceptScore W3131210460C71924100 @default.
• W3131210460 hasConceptScore W3131210460C86803240 @default.
• W3131210460 hasIssue "4_Supplement" @default.
• W3131210460 hasLocation W31312104601 @default.
• W3131210460 hasOpenAccess W3131210460 @default.
• W3131210460 hasPrimaryLocation W31312104601 @default.
• W3131210460 hasRelatedWork W1976264124 @default.
• W3131210460 hasRelatedWork W1977676876 @default.
• W3131210460 hasRelatedWork W1994243402 @default.
• W3131210460 hasRelatedWork W2073937368 @default.
• W3131210460 hasRelatedWork W2106461043 @default.
• W3131210460 hasRelatedWork W2154217167 @default.
• W3131210460 hasRelatedWork W2170633385 @default.
• W3131210460 hasRelatedWork W2347908727 @default.
• W3131210460 hasRelatedWork W3131210460 @default.
• W3131210460 hasRelatedWork W68729977 @default.
• W3131210460 hasVolume "81" @default.
• W3131210460 isParatext "false" @default.
• W3131210460 isRetracted "false" @default.
• W3131210460 magId "3131210460" @default.
• W3131210460 workType "article" @default.